PE-22-28 Peptide Research: 7 Key Findings on TREK-1 and Spadin-Derived Neurobiology
Exploring the seven-amino-acid sortilin propeptide fragment, potassium-channel inhibition, experimental antidepressant-like activity, neuronal plasticity and the limitations of human evidence.
PE-22-28 peptide research examines a synthetic heptapeptide developed from spadin, a naturally occurring fragment of the sortilin propeptide. Its principal scientific interest lies in its ability to inhibit TREK-1, a two-pore-domain potassium channel involved in regulating neuronal electrical activity.
The compound was described in detail in a 2017 study published in Frontiers in Pharmacology. Researchers identified a shortened seven-residue sequence that retained the ability to inhibit TREK-1 and showed substantially greater potency than the original 17-residue spadin peptide under the experimental conditions.
The same study examined behavioural responses in mice, neuronal cell proliferation, synaptic markers and the duration of experimental effects.
These findings made PE-22-28 an interesting subject for research into potassium-channel biology and the development of compounds with antidepressant-like properties.
However, PE-22-28 peptide research remains preclinical. Cell-based inhibition of a potassium channel and behavioural changes in mice do not establish effectiveness against human depression.
The distinction is especially important because PE-22-28 is sometimes incorrectly described as a fragment of spexin, a different neuropeptide. Its documented structural origin is the sortilin propeptide, and its relationship with spadin is central to understanding the published experiments.
This guide examines seven major scientific findings, compares PE-22-28 with its related analogues and explains the analytical considerations relevant to laboratory research.
1. PE-22-28 Peptide Research: Structure, Sequence and Sortilin Origins
PE-22-28 is a synthetic peptide containing seven amino acid residues.
Its conventional sequence is:
Gly–Val–Ser–Trp–Gly–Leu–Arg
In single-letter notation:
GVSWGLR
The name refers to residues 22 through 28 of the sortilin propeptide.
Molecular Specifications
| Property | Scientific information |
|---|---|
| Compound | PE-22-28 |
| Alternative designation | PE(22–28), mini-spadin |
| Structural origin | Sortilin propeptide |
| Peptide class | Synthetic heptapeptide |
| Sequence | Gly–Val–Ser–Trp–Gly–Leu–Arg |
| Single-letter sequence | GVSWGLR |
| Residue count | 7 |
| Molecular formula | C35H55N11O9 |
| Approximate molecular mass | 773.9 Da |
| CAS number | 1801959-12-5 |
| PubChem CID | 165437303 |
| Principal experimental target | TREK-1 potassium channel |
| US regulatory status | Not an FDA-approved medicine |
These specifications refer to the unmodified peptide. Chemically modified analogues and different supplied forms require their own analytical specifications.
What Is Sortilin?
Sortilin is a membrane-associated protein involved in intracellular trafficking and the handling of certain signalling molecules.
It is produced as a precursor that undergoes processing.
One part of this precursor is known as the sortilin propeptide.
Where Does Spadin Come From?
Spadin corresponds to residues 12–28 of the sortilin propeptide.
It contains 17 amino acid residues.
Researchers previously identified spadin as a peptide capable of inhibiting TREK-1 activity.
How Was PE-22-28 Developed?
Investigators studying spadin degradation identified shorter peptide fragments.
They then compared different sequences to determine whether the TREK-1-inhibiting activity could be retained in a smaller molecule.
The seven-residue PE-22-28 sequence emerged as a particularly active fragment.
Is PE-22-28 a Spexin Fragment?
No.
Spexin is a different peptide with a different sequence.
The correct origin of PE-22-28 is the sortilin propeptide.
Why Does the Distinction Matter?
Misidentifying the parent protein can lead to incorrect assumptions about receptor targets and biological mechanisms.
Accurate molecular identity is the foundation of PE-22-28 peptide research.
2. PE-22-28 Peptide Research and TREK-1 Potassium-Channel Inhibition
The most direct mechanistic evidence for PE-22-28 concerns the TREK-1 channel.
TREK-1 belongs to the two-pore-domain potassium-channel family, commonly abbreviated K2P.
The channel is encoded by the KCNK2 gene.
What Does TREK-1 Do?
TREK-1 contributes to background potassium conductance in certain cells.
Potassium movement across the cell membrane helps influence electrical potential.
In neurons, this can affect excitability and responses to signalling inputs.
What Is a Background Potassium Channel?
Background potassium channels contribute to the electrical properties of cells even when they are not responding to a conventional neurotransmitter.
Their activity helps establish the conditions under which neurons generate electrical signals.
Why Was TREK-1 Studied in Depression Research?
Earlier animal research identified a relationship between TREK-1 activity and behavioural responses in experimental depression models.
This prompted interest in whether inhibiting the channel could produce antidepressant-like effects.
The 2017 Electrophysiology Study
Djillani and colleagues examined PE-22-28 using HEK cells engineered to express human TREK-1 channels.
They measured electrical currents with the patch-clamp technique.
What Is Patch-Clamp Recording?
Patch-clamp electrophysiology measures electrical currents across cell membranes.
It is commonly used to study ion-channel activity.
What Did Researchers Find?
The investigators reported that PE-22-28 inhibited TREK-1 currents at very low concentrations.
The reported half-maximal inhibitory concentration was approximately 0.12 nanomolar.
What Does IC50 Mean?
IC50 represents the concentration associated with 50% inhibition of a measured response under defined experimental conditions.
A lower IC50 can indicate greater inhibitory potency in the assay.
However, it does not independently establish better clinical effectiveness.
How Did PE-22-28 Compare With Spadin?
The researchers reported a TREK-1 IC50 of approximately 40–60 nanomolar for the original spadin peptide.
PE-22-28 therefore showed substantially greater potency in the experimental system.
Does This Establish a Human Antidepressant Effect?
No.
The result demonstrates ion-channel inhibition in a laboratory model.
It does not establish that the same exposure, target engagement or clinical effect occurs in humans.
Scientific Interpretation
PE-22-28 peptide research provides direct preclinical evidence of TREK-1 inhibition.
This is the strongest mechanistic basis for studying the compound, but clinical significance remains unestablished.
3. PE-22-28 Peptide Research: Selectivity Across Potassium Channels
A compound that inhibits one ion channel may also interact with other channels.
This matters because potassium channels participate in numerous physiological functions.
Why Selectivity Matters
A compound with broad ion-channel activity may influence multiple tissues.
Selectivity testing helps researchers determine whether the measured response is relatively specific to the intended target.
Which Channels Were Examined?
The 2017 investigators tested PE-22-28 against several related potassium channels.
These included TREK-2, TRAAK, TRESK and TASK-1.
What Were the Findings?
Under the tested conditions, PE-22-28 did not produce comparable inhibition of those channels.
This supported a degree of selectivity for TREK-1 within the experimental panel.
Does This Mean PE-22-28 Is Completely Selective?
No.
Testing a limited group of channels cannot establish the absence of interactions with every possible molecular target.
What About hERG?
The study also examined the human ether-à-go-go-related gene potassium channel, commonly known as hERG.
This channel is important in cardiac electrical repolarisation.
Why Is hERG Testing Relevant?
Some compounds that inhibit hERG can interfere with cardiac electrical activity.
For this reason, hERG screening is a common component of early pharmacological research.
What Did the Study Report?
The researchers did not observe an effect on the measured hERG current under the tested conditions.
Does This Prove Cardiac Safety?
No.
A negative result in a cell-based hERG assay does not establish comprehensive cardiovascular safety.
Other cardiac channels, exposure conditions and physiological systems may also be relevant.
What Additional Tests Would Be Needed?
A broader safety evaluation would require additional pharmacology, toxicology and exposure studies.
Research Interpretation
PE-22-28 peptide research suggests preferential TREK-1 inhibition within the published screening panel.
However, selectivity in a laboratory assay is not equivalent to a complete human safety profile.
4. PE-22-28 Peptide Research and Antidepressant-Like Behaviour in Mice
The 2017 study also examined whether TREK-1 inhibition corresponded with changes in animal behaviour.
These experiments used established behavioural paradigms.
The Forced Swim Test
The forced swim test measures aspects of rodent behaviour in an inescapable water environment.
Researchers commonly record immobility and other behavioural responses.
What Did the Investigators Observe?
Mice exposed to PE-22-28 and selected related analogues showed reduced immobility compared with controls under the experimental conditions.
Why Is the Result Interesting?
The behavioural findings accompanied evidence of TREK-1 inhibition.
This supported further investigation of the relationship between potassium-channel activity and behavioural responses.
Does Reduced Immobility Mean Depression Was Treated?
No.
The forced swim test does not reproduce the full clinical features of human major depressive disorder.
Changes in immobility can also be influenced by movement, stress responses and other factors.
The Novelty-Suppressed Feeding Test
Researchers also examined behaviour in a novelty-suppressed feeding paradigm.
This test evaluates feeding-related behaviour in an unfamiliar environment.
What Was Reported?
The study found a reduction in the latency to begin feeding after repeated experimental exposure to PE-22-28.
Does This Establish Reduced Human Anxiety?
No.
An animal behavioural endpoint cannot establish treatment effectiveness for a human psychiatric condition.
Why Multiple Tests Help
Different behavioural tests examine different aspects of animal responses.
Consistent findings across models can strengthen a preclinical hypothesis.
However, they do not replace human clinical trials.
How Should These Findings Be Described?
The appropriate term is antidepressant-like activity in experimental animal models.
Calling PE-22-28 a proven antidepressant would exceed the available evidence.
Scientific Interpretation
PE-22-28 peptide research supports further investigation of TREK-1 inhibition in behavioural neurobiology.
Its effects in humans remain unknown.
5. PE-22-28 Peptide Research and Neuronal Plasticity
Researchers have also examined cellular processes associated with the development and organisation of neural connections.
Two areas discussed in the literature are neurogenesis and synaptogenesis.
What Is Neurogenesis?
Neurogenesis refers to the production of new neurons from precursor cells.
Its extent and regulation vary by species, brain region and developmental stage.
What Is Synaptogenesis?
Synaptogenesis refers to the formation of synaptic connections between neurons.
Synapses are specialised structures involved in communication between nerve cells.
What Did the 2017 Study Examine?
The investigators assessed markers associated with neurogenesis in mice following experimental exposure to spadin-derived peptides.
They also examined synaptic-associated proteins in cultured cortical neurons.
What Were the Neurogenesis Findings?
Selected PE-22-28-related compounds increased experimental measures associated with neurogenesis.
The magnitude of the response varied among the analogues.
Were All Analogues Equally Active?
No.
The study reported differences between the original PE-22-28 sequence and chemically modified derivatives.
This demonstrates the importance of precise molecular identification.
What Is PSD-95?
Postsynaptic density protein 95, abbreviated PSD-95, is a scaffolding protein associated with certain excitatory synapses.
Researchers use it as one marker in studies of synaptic organisation.
What Did Researchers Observe?
The study reported increased PSD-95-associated measurements in cultured cortical neurons exposed to selected peptides.
Does Increased PSD-95 Prove Better Memory?
No.
An increase in a synaptic marker does not automatically establish improved learning, memory or cognition.
Why Functional Measurements Matter
Changes in protein abundance should be evaluated alongside functional measurements where possible.
A structural or molecular marker is not a substitute for demonstrating a meaningful physiological outcome.
Does PE-22-28 Regenerate the Human Brain?
There is no reliable clinical evidence supporting that claim.
Research Interpretation
PE-22-28 peptide research includes preclinical findings involving neuronal plasticity markers.
These results provide hypotheses for future work rather than proof of human neurological regeneration.
6. PE-22-28 Peptide Research: Stability and Modified Spadin Analogues
The development of PE-22-28 was motivated partly by limitations associated with the original spadin peptide.
Researchers wanted to identify shorter compounds with favourable experimental characteristics.
Why Shorten a Peptide?
Shorter sequences may differ in enzymatic stability, synthesis characteristics and molecular interactions.
However, a shorter peptide is not automatically more stable or more biologically active.
What Did Researchers Observe With Spadin?
Earlier studies reported that spadin’s experimental activity declined over time in vivo.
This motivated investigations into its degradation products.
How Was PE-22-28 Selected?
Researchers screened shortened fragments for their ability to inhibit TREK-1.
PE-22-28 retained substantial activity and showed higher potency than spadin in the reported assays.
What Is G/A-PE-22-28?
This analogue replaces the first glycine residue of PE-22-28 with alanine.
Its sequence is:
Ala–Val–Ser–Trp–Gly–Leu–Arg
The single-letter sequence is AVSWGLR.
Is This the Same Compound?
No.
Changing glycine to alanine produces a chemically distinct peptide.
What Is Biotinylated G/A-PE-22-28?
It is a modified derivative containing a biotin group.
This modification changes the compound’s chemical identity and may influence its experimental behaviour.
What Did the Study Report About Duration?
The investigators reported prolonged experimental activity for selected spadin-derived analogues compared with the parent peptide.
However, results differed among the tested structures and endpoints.
Does This Establish a Human Half-Life?
No.
Animal pharmacological duration is not equivalent to a validated human elimination half-life.
What About Blood–Brain Barrier Transport?
The study discussed modifications intended to influence peptide distribution and brain exposure.
However, an assumed improvement in brain delivery should not be treated as proven human pharmacokinetic behaviour.
Why Modified Analogues Must Be Distinguished
A finding involving G/A-PE-22-28 or a biotinylated derivative should not automatically be attributed to unmodified PE-22-28.
Scientific Interpretation
PE-22-28 peptide research demonstrates that small structural changes can substantially alter experimental potency and behaviour.
This is an important example of peptide structure–activity relationships.
7. PE-22-28 Peptide Research: Human Evidence, Safety and Regulatory Limitations
The central limitation is the absence of established human clinical evidence.
Has PE-22-28 Been Studied in Human Clinical Trials?
No published controlled human clinical trial establishing its safety or effectiveness was identified in the available literature reviewed for this article.
Is PE-22-28 FDA-Approved?
No.
PE-22-28 is not an FDA-approved medicine.
Is It an Approved Antidepressant?
No.
There is no established regulatory approval for treating depression or other psychiatric disorders.
What About Human Safety?
The available evidence is insufficient to establish a comprehensive human safety profile.
Does TREK-1 Selectivity Establish Safety?
No.
Ion-channel selectivity in cell experiments is one component of preclinical evaluation.
It does not replace toxicology, pharmacokinetic studies or controlled clinical trials.
What About Long-Term Exposure?
Long-term human effects remain unknown.
Can Mouse Behaviour Predict Human Clinical Outcomes?
Animal experiments can help generate hypotheses.
However, behavioural findings do not reliably predict clinical effectiveness in every case.
Why Is Independent Replication Important?
A substantial portion of the PE-22-28 literature originates from the same research programme.
Independent replication would help determine the robustness and generalisability of the findings.
What Research Questions Remain?
Important questions include target engagement in living tissues, peptide metabolism, brain exposure, effects on additional molecular targets and the relationship between TREK-1 inhibition and clinically meaningful outcomes.
The Main Evidence Boundary
PE-22-28 peptide research remains an experimental field.
Its established laboratory findings should not be presented as proof of an effective or safe human treatment.
PE-22-28 Peptide Research: Evidence Summary
| Research area | Evidence available | Appropriate interpretation |
|---|---|---|
| Molecular sequence | Established structural identity | Seven-residue sortilin propeptide fragment |
| TREK-1 inhibition | Cell-based patch-clamp experiments | Potent inhibition reported |
| Comparison with spadin | In vitro studies | Greater inhibitory potency under tested conditions |
| TREK-2, TRAAK, TRESK and TASK-1 | Cell-based screening | No comparable inhibition reported |
| hERG screening | Cell-based electrophysiology | No effect reported under tested conditions |
| Antidepressant-like behaviour | Mouse experiments | Changes in behavioural endpoints |
| Neurogenesis markers | Preclinical experiments | Increased markers reported |
| PSD-95 and synaptic measurements | Cultured neuronal experiments | Changes in selected synaptic markers |
| Pharmacological duration | Animal research | Analogue-dependent findings |
| Human depression | No established controlled clinical evidence | Effectiveness unproven |
| Long-term human safety | Insufficient evidence | Safety unknown |
| FDA approval | Regulatory status | Not approved |
PE-22-28 Laboratory Testing: Identity, Purity and Stability
Accurate analytical characterisation is particularly important when comparing PE-22-28 with structurally similar analogues.
Sequence Confirmation
The intended sequence is GVSWGLR.
A sample containing AVSWGLR represents the glycine-to-alanine analogue, not the original peptide.
HPLC Purity Testing
High-performance liquid chromatography can separate the target compound from selected impurities.
A chromatographic main-peak area percentage does not establish absolute peptide content. PE-22-28 peptide research
LC-MS Analysis
Liquid chromatography–mass spectrometry can provide evidence of molecular identity and detect certain related substances.
Tryptophan-Associated Degradation
PE-22-28 contains tryptophan.
This residue can be susceptible to chemical changes under certain environmental conditions.
Stability studies should therefore examine the actual supplied formulation. PE-22-28 peptide research
Terminal Modifications
N-terminal and C-terminal modifications can change molecular mass and chemical behaviour.
The analytical specification should identify whether the material is unmodified or derivatised. PE-22-28 peptide research
Peptide Content
Total sample mass may include counterions, water and other constituents.
Nominal vial mass should be distinguished from analytically determined peptide content.
Batch-Specific Documentation
A meaningful Certificate of Analysis should identify the batch, material, analytical methods and reported results.
Sterility and Endotoxins
Molecular identity and chromatographic purity do not establish sterility or endotoxin status.
These require separate testing where relevant.
Why This Matters
PE-22-28 peptide research frequently compares compounds differing by a single residue or terminal modification.
Using an incorrectly identified material could invalidate conclusions about potency, selectivity or stability. PE-22-28 peptide research
Worked Example: Interpreting TREK-1 Inhibition
Consider a hypothetical laboratory experiment measuring TREK-1 current in engineered cells.
The untreated activated-channel condition is assigned a relative current of 100%.
| Experimental condition | Hypothetical relative TREK-1 current |
|---|---|
| Activated-channel control | 100% |
| Experimental group A | 78% |
| Experimental group B | 44% |
| Experimental group C | 19% |
These values are fictional and illustrate data interpretation only. PE-22-28 peptide research
What Does the Table Show?
Lower current values suggest greater inhibition of the measured channel activity.
Does This Establish a Specific IC50?
No.
Determining an IC50 requires an appropriately designed concentration–response experiment and suitable curve fitting. PE-22-28 peptide research
Does Greater Inhibition Mean Better Clinical Effectiveness?
No.
Cell-based potency does not independently establish therapeutic benefit. PE-22-28 peptide research
What Additional Controls Would Help?
Relevant controls include cell viability, channel-expression verification, vehicle controls and testing against additional ion channels.
What Is the Main Lesson?
PE-22-28 peptide research depends on distinguishing molecular target inhibition from biological and clinical outcomes.
PE-22-28 Compared With Spadin and Related Analogues
| Compound | Structure | Research distinction |
|---|---|---|
| Spadin | 17-residue sortilin propeptide fragment | Original TREK-1-inhibiting peptide |
| PE-22-28 | GVSWGLR | Shortened seven-residue TREK-1 inhibitor |
| G/A-PE-22-28 | AVSWGLR | Glycine-to-alanine modified analogue |
| Biotinylated G/A-PE-22-28 | Modified AVSWGLR derivative | Analogue examined for altered experimental properties |
| Spexin | Unrelated 14-residue neuropeptide | Different molecular origin and receptor biology |
These compounds should not be treated as interchangeable.
The distinction between PE-22-28 and spexin is especially important because they do not share the same structural origin. PE-22-28 peptide research
Related Axion Peptide Lab Research Guides
Peptide Structure–Activity Relationships
Verify that these proposed internal article URLs are published before adding them as live links.
PE-22-28 Research Materials at Axion Peptide Lab
Axion Peptide Lab provides a catalogue relevant to laboratory peptide research.
Researchers evaluating PE-22-28 should consult current product specifications and available batch documentation.
What Should Laboratories Verify?
Relevant specifications include the exact amino acid sequence, terminal groups, chemical form, nominal content and batch identification. PE-22-28 peptide research
Why Is Sequence Verification Important?
PE-22-28 and G/A-PE-22-28 differ by one amino acid residue.
They are distinct compounds with potentially different experimental characteristics.
Does High Purity Establish TREK-1 Activity?
No.
Chromatographic purity does not independently establish functional ion-channel inhibition.
Research-Only Distinction
PE-22-28 research materials should not be represented as approved medicines or clinically validated treatments for depression. PE-22-28 peptide research
Frequently Asked Questions About PE-22-28 Peptide Research
1. What is PE-22-28 peptide research?
PE-22-28 peptide research examines a seven-amino-acid sortilin propeptide fragment, particularly its effects on TREK-1 potassium channels and experimental neurological responses.
2. What is the PE-22-28 amino acid sequence?
The sequence is Gly–Val–Ser–Trp–Gly–Leu–Arg, abbreviated GVSWGLR.
3. Is PE-22-28 derived from spadin?
Yes. PE-22-28 corresponds to the final seven residues of the longer spadin peptide.
4. Is PE-22-28 a spexin fragment?
No. PE-22-28 originates from the sortilin propeptide, not spexin.
5. Does PE-22-28 inhibit TREK-1?
Yes. Cell-based electrophysiology studies reported potent inhibition of TREK-1 activity.
6. Is PE-22-28 more potent than spadin?
The 2017 study reported a lower TREK-1 IC50 for PE-22-28 than for spadin under the tested conditions.
7. Has PE-22-28 been studied for depression?
Yes. Researchers examined antidepressant-like behavioural responses in mice. These findings do not establish effectiveness in humans.
8. Does PE-22-28 promote neurogenesis?
Selected preclinical experiments reported changes in neurogenesis-associated measurements. Human neurological benefits have not been established.
9. Is PE-22-28 FDA-approved?
No. PE-22-28 is not an FDA-approved medicine.
10. How can laboratories verify PE-22-28 quality?
Relevant approaches include HPLC, LC-MS, sequence-related identity testing and batch-specific analytical documentation.
Conclusion: What PE-22-28 Peptide Research Establishes
PE-22-28 peptide research has produced important preclinical findings involving TREK-1 potassium-channel inhibition and experimental neuronal responses.
The peptide’s structural identity is well defined.
Its sequence corresponds to seven residues of the sortilin propeptide and forms the C-terminal region of spadin.
The 2017 research programme reported greater TREK-1 inhibitory potency than the original spadin peptide, together with changes in mouse behavioural tests and selected neuronal plasticity markers.
These observations support continued research into the relationship between background potassium channels and neural signalling.
However, the evidence remains preclinical.
There is no established controlled human clinical evidence demonstrating that PE-22-28 safely or effectively treats depression or improves neurological function.
For laboratories, accurate identification of the peptide and its analogues is essential.
The most defensible conclusion is that PE-22-28 is a potent experimental TREK-1 inhibitor with promising mechanistic findings, not an established human antidepressant.
Scientific References
- Djillani A, Mazella J, Heurteaux C, Borsotto M. (2017). Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Frontiers in Pharmacology, 8, 643.
https://doi.org/10.3389/fphar.2017.00643 - Mazella J, Pétrault O, Lucas G, et al. (2010). Spadin, a Sortilin-Derived Peptide, Targeting Rodent TREK-1 Channels: A New Concept in the Antidepressant Drug Design. PLoS Biology, 8(4), e1000355.
https://doi.org/10.1371/journal.pbio.1000355 - Heurteaux C, Lucas G, Guy N, et al. (2006). Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nature Neuroscience, 9, 1134–1141.
https://doi.org/10.1038/nn1749 - Moha Ou Maati H, Veyssiere J, Labbal F, et al. (2012). Spadin as a new antidepressant: absence of TREK-1-related side effects. Neuropharmacology.
https://pubmed.ncbi.nlm.nih.gov/?term=Moha+Ou+Maati+spadin+2012 - PubChem. PE-22-28 compound information.
https://pubchem.ncbi.nlm.nih.gov/compound/165437303 - PubMed. PE-22-28 and spadin biomedical literature.
https://pubmed.ncbi.nlm.nih.gov/?term=PE-22-28+spadin - ClinicalTrials.gov. Registered clinical research search for PE-22-28.
https://clinicaltrials.gov/search?term=PE-22-28
These references support the scientific discussion. They do not verify the identity, purity, safety or clinical suitability of independently supplied research materials.
Research-use notice: This article is provided for scientific education and legitimate laboratory research. Axion Peptide Lab research materials are not intended for human or veterinary administration. Experimental findings should not be interpreted as medical advice, administration guidance or established claims of therapeutic benefit.